Edwards Lifesciences Corporation $EW Stake Boosted by Focus Partners Advisor Solutions LLC

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Edwards Lifesciences by 76.2% during Q1, bringing its total holdings to 7,389 shares valued at approximately $535,000.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding estimates, and a revenue of $1.53 billion, up 11.9% year-over-year.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Edwards Lifesciences, with a price target averaging $85.90.

Focus Partners Advisor Solutions LLC increased its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 76.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,389 shares of the medical research company's stock after purchasing an additional 3,195 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Edwards Lifesciences were worth $535,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of EW. Jennison Associates LLC boosted its position in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after acquiring an additional 2,576,383 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Edwards Lifesciences by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock worth $482,621,000 after acquiring an additional 513,468 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Edwards Lifesciences by 24.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 4,615,163 shares of the medical research company's stock worth $341,661,000 after acquiring an additional 921,500 shares during the period. Nuveen LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $330,881,000. Finally, Invesco Ltd. boosted its position in Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock worth $310,773,000 after acquiring an additional 107,241 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.1%

EW opened at $80.89 on Friday. The business has a 50 day moving average price of $78.77 and a 200 day moving average price of $75.21. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market cap of $47.49 billion, a P/E ratio of 11.64, a price-to-earnings-growth ratio of 3.91 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company earned $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Wells Fargo & Company raised their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Evercore ISI lifted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a report on Friday, July 25th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Finally, Piper Sandler lifted their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,014 shares of company stock worth $1,698,844. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.